CN1425659A - Process for preparing danshen salviandic acid - Google Patents
Process for preparing danshen salviandic acid Download PDFInfo
- Publication number
- CN1425659A CN1425659A CN 02160771 CN02160771A CN1425659A CN 1425659 A CN1425659 A CN 1425659A CN 02160771 CN02160771 CN 02160771 CN 02160771 A CN02160771 A CN 02160771A CN 1425659 A CN1425659 A CN 1425659A
- Authority
- CN
- China
- Prior art keywords
- acid
- water
- salvianolic acid
- extraction
- impurity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 244000132619 red sage Species 0.000 title claims abstract description 16
- 239000002253 acid Substances 0.000 title claims description 18
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 72
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 claims abstract description 56
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 claims abstract description 55
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 claims abstract description 55
- 230000008569 process Effects 0.000 claims abstract description 37
- 238000000605 extraction Methods 0.000 claims abstract description 19
- 239000007788 liquid Substances 0.000 claims abstract description 14
- 238000003809 water extraction Methods 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- 240000007164 Salvia officinalis Species 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 235000005412 red sage Nutrition 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 28
- 239000012535 impurity Substances 0.000 claims description 27
- 239000007864 aqueous solution Substances 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 238000004440 column chromatography Methods 0.000 claims description 15
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 14
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 238000010828 elution Methods 0.000 claims description 10
- 235000017276 Salvia Nutrition 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000005554 pickling Methods 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 238000005325 percolation Methods 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 238000004062 sedimentation Methods 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 235000014347 soups Nutrition 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 238000013459 approach Methods 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000003456 ion exchange resin Substances 0.000 claims description 3
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 239000010409 thin film Substances 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 238000004237 preparative chromatography Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 238000013375 chromatographic separation Methods 0.000 abstract 1
- 238000011097 chromatography purification Methods 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 238000011026 diafiltration Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 238000002386 leaching Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 238000007598 dipping method Methods 0.000 description 5
- 239000008899 fufang danshen Substances 0.000 description 5
- 238000009413 insulation Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000004064 recycling Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 229930183118 Tanshinone Natural products 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 150000007965 phenolic acids Chemical class 0.000 description 3
- 235000009048 phenolic acids Nutrition 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 238000002137 ultrasound extraction Methods 0.000 description 3
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 2
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical class C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- -1 diterpene quinones Chemical class 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- YMGFTDKNIWPMGF-AGYDPFETSA-N 3-(3,4-dihydroxyphenyl)-2-[(e)-3-[2-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid Chemical compound C=1C=C(O)C(O)=C(\C=C\C=2C=C(O)C(O)=CC=2)C=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-AGYDPFETSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GJHXGOBGPWPCCK-UHFFFAOYSA-N blechnic acid Natural products OC(=O)C1C=2C(C=CC(=O)O)=CC=C(O)C=2OC1C1=CC=C(O)C(O)=C1 GJHXGOBGPWPCCK-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 229930183842 salvianolic acid Natural products 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention process of danshen salvianolic acid B includes the technological steps of: water extraction; acidifying extractive liquid; column chromatographic separation and purification of salvianolic acid B; and drying. The said process has high extraction rate and high purity, and the extracted product has salvianolic acid B content as high as 90% and stale quality. The present invention is suitable for large scale production.
Description
Technical field
The present invention relates to a kind of preparation method of salvianolic acid B from salvia miltiorrhiza.The structural formula of salvianolic acid B is as follows:
Background technology
The red sage root is one of common drug in China's traditional medicine, and the red sage root has clinical application basis widely as the medicine of treatment cardiovascular disease, and evident in efficacy, and long clinical application history is arranged.Modern pharmacology shows that the pharmacological action of the red sage root mainly is to cardio-cerebrovascular, and energy vasodilation, quickening blood flow are anti-oxidant, microcirculation improvement, change viscosity of blood, anticoagulation, increase blood supply of cardiac muscle amount, oxygen-supplying amount, reduction myocardial consumption of oxygen, anti-hepatic fibrosis etc.Be used for the treatment of cardiovascular disorder and diseases such as hepatic fibrosis, renal failure such as stenocardia, myocardial infarction.
Recent years, many experts use the modern medicine method, in conjunction with multi-disciplinary technique means such as chemistry, molecular biology and cytobiologies, the red sage root have been carried out than systematic research, have obtained a large amount of new understanding and experimental result.Salvia-soluble effective constituent is the important activity composition of the red sage root, is subjected to medical circle and payes attention to greatly.Water soluble component comprises rancinamycin IV, Salvianic acidA and salvianolic acid A, B, C, D, E etc., wherein the composition activity of phenolic acids is the strongest, and is remarkable with the effect of salvianolic acid B especially, confirms through pharmacodynamic experiment, it has significant anti peroxidation of lipid, removes free radical and antithrombotic effect.
Cardiovascular system diseases is the elderly's height morbidity.The developing the salvianolic acid B series product and will do and provide big contribution of success for the mankind prevent and treat cardiovascular diseases.
In recent years, the report about the extraction of the red sage root and the clinical application of red sage compound preparation was a lot.The preparation that the red sage root is used separately is less, generally is to form compound preparation with other medicines to be applied to clinical.A lot of formulations have appearred, as FUFANG DANSHEN PIAN, FUFANG DANSHEN DIWAN, compound Salviae Miltiorrhizae electuary, FUFANG DANSHEN JIAONANG, compound Salviae Miltiorrhizae granule, compound Salviae Miltiorrhizae aerosol, compound injection of red sage root, compound Salviae Miltiorrhizae oral liquid etc.More wide prospect has been opened up in succeeding in developing to the clinical application of the red sage root of these products.But mostly these products are to adopt the old technology of poach alcohol deposition method or ethanol-extracted, the aqueous soluble active constituent major part of the red sage root is lost or destroyed in the leaching process, and oil-soluble impurities content is higher even most its fat-soluble component that kept, wherein based on the TANSHINONES of diterpene quinones.Portioned product has kept more water soluble component, but also mainly is rancinamycin IV, Salvianic acidA, obtains because of its two kinds of compositions more easily separate from medicinal material, and these two kinds of compositions are likely the degradation production of salvianolic acid class, and wherein the toxic side effect of rancinamycin IV is bigger.Nonactive component content is very high in traditional in addition extraction process products obtained therefrom crude drug in whole, and extract weight is generally about 20% of crude drug in whole, and wherein major part is an inactive substance.
Traditional red sage formulation adopts alcohol extracting method more.As according to " red sage root need extract three times in Chinese pharmacopoeia (version was an one in the 2000) FUFANG DANSHEN PIAN, for the first time adds alcohol reflux 1.5 hours, filter, filtrate recycling ethanol, being concentrated into relative density is 1.30; Add for the second time 50% alcohol reflux 1.5 hours, filter; Add water for the third time and refluxed 2 hours, filter.Merge second and third time filtrate, reclaim ethanol, being concentrated into relative density is 1.40, merges with primary concentrated solution, and mixing is made cream clearly.Effective component in red sage in the made FUFANG DANSHEN PIAN of this alcohol extraction process is based on the TANSHINONES of diterpene quinones, and water soluble component is lost substantially.
" pharmaceutical preparation note " (People's Health Publisher 1983.402) disclosed compound injection of red sage root adopts the poach alcohol deposition method, and the red sage root is cleaned back water boiling and extraction three times, filters, and merges three times decocting liquid, is concentrated into every ml and contains medicinal material 1.5～2g.Adding 95% ethanol makes soup contain alcohol amount to reach 75%, place 40 hours after-filtration, filtrate recycling ethanol also is concentrated into every ml and contains medicinal material 3g, adding 95% ethanol at last makes soup contain alcohol amount to reach 85%, place filtration in 4 hours, filtrate recycling ethanol is concentrated into every ml and contains medicinal material 3～5g, pours 13 times distilled water, place 24 hours after-filtration, filtrate recycling ethanol also is concentrated into nothing alcohol flavor.Salvianolic acid B is the four poly-coffic acid compounds that two molecule Salvianic acidAs and the condensation of a part Prolithospermic acid form, extremely unstable at 100, easily be degraded into the caffeinic dehydration of monomer Salvianic acidA and oligomerization, decarboxylate, or being oxidized to rancinamycin IV, Protocatechuic Acid, the effective ingredient salvianolic acid B is most of destroyed behind the poach three times.Different alcohol precipitation concentrations is also bigger to the active constituent content influence of the red sage root, because of phenolic acids composition many forms with salt such as magnesium, potassium, ammonia in plant exist, easily molten and poorly soluble in alcohol in water, 70% alcohol is deposited in when removing impurity, and water-soluble phenolic acids effective ingredient loss amount can reach more than 50%.
Summary of the invention
Technical problem to be solved by this invention is, overcomes the defective that prior art exists, and a kind of preparation method of effective preparation method, especially salvianolic acid B from salvia miltiorrhiza of salvia-soluble composition is provided.
The preparation method of salvianolic acid B from salvia miltiorrhiza of the present invention, its processing step is:
1. water extraction
Under 0～99 ℃ temperature, use the water-soluble components in the water extraction red sage root.
Institute's water can be ordinary water, distilled water, deionized water, reverse osmosis water etc.Can contain micro-acid, alkali, inorganic salt, organic salt, alcohols etc. in the water.
The method of extracting can adopt pickling process, also can adopt percolation process, ultrasonic extraction or microwave extraction method.
Above-mentioned pickling process can be extracted for single-steeping, and also can be repeatedly, dipping extracts.Now the method with twice dipping extraction is that example describes.
Dipping is got red sage root crude drug and is made medicine materical crude slice for the first time, or pulverizes with other proper method, and it is an amount of to add water, and amount of water is generally 6～15 times of medicinal material amount, low temperature or insulation dipping.Can be prior to soaking (soak i.e. dipping herein, both be same meaning) below 40 ℃, and then be heated to 40～99 ℃ of insulation immersions.Suggested design is: amount of water is about 10 times of red sage root amount, and first soak at room temperature 1～4 hour is heated to 40～70 ℃ then, soaks 2～6 hours.Separate extracting solution for the first time.
Flood for the second time, it is an amount of to add water, and amount of water is generally 4～10 times of medicinal material amount.After certain hour is soaked in 40～99 ℃ of insulations, separate obtaining second batch of extracting solution.Suggested design is: amount of water is 8 times of red sage root amount, is heated to 40～70 ℃, soaks 2～6 hours.
Merge extracted twice liquid, adopt the method for filtration, natural sedimentation or centrifuging, tentatively remove the solid impurity in the extracting solution.
Above-mentioned percolation process concrete grammar be get salvia piece or pulverize with other method after the red sage root, be loaded in the diafiltration post or bucket that a synthetic glass makes, limit rim appropriate compacting, about 1/5 volume is reserved in diafiltration post or bucket upper end.Add water to all medicinal material submergences, static immersion 4 hours.Open diafiltration post lower end valve, percolate is slowly flowed out, the amount that per hour flows out percolate is about a times of red sage root dry weight, constantly injects water simultaneously to diafiltration post upper end.With FeCl
3Point sample is observed the content of salvianolic acid B in the percolate, stops diafiltration when more weak to color reaction.
Above-mentioned ultrasonic method concrete grammar is on the basis of pickling process, and leaching process is finished under ultrasonic wave.Ultrasound assisted extraction technique mainly is that the leaching that utilizes cavitation effect of ultrasonic waves to quicken effective ingredients in plant is extracted, and hyperacoustic in addition second-order effect adds mechanical vibration, emulsification, diffusion.Smash, chemical effect etc. also can be quickened diffusion release and abundant and the solvent that desire is extracted composition, is beneficial to extraction.
Above-mentioned microwave method concrete grammar is on the basis of pickling process, and leaching process is finished under microwave.Microwave is the new technology that a kind of recent development of utilizing micro-wave energy to improve extraction yield is got up.Its principle is in microwave field, the difference that absorbs the microwave ability makes some zone of base matter or some component in the extraction system be heated by selectivity, thereby make that be extracted material separates from matrix or system, enter into that specific inductivity is less, the solvent of microwave absorption capacity relative mistake.
2. acidizing extracting liquid
To add inorganic in the above-mentioned steeping fluid or organic acid accent pH, making steeping fluid pH value be 1～6, adopts the method for filtration, natural sedimentation or centrifuging, removes the solid impurity that occurs after the acidifying.Wherein used acid can be hydrochloric acid, sulfuric acid, phosphoric acid, formic acid, acetate etc.The best is hydrochloric acid or sulfuric acid.
The acidifying purpose is as follows: the salvianolic acid constituents in (1) red sage root mainly exists with the form of salt, and magnesium salts is arranged, and sylvite, ammonia salt etc. are also arranged, and its composition is complicated.After being acidified with acid, become single salvianolic acid B, help the control of quality standard.(2) contain a large amount of colloid class impurity in the steeping fluid, by acidifying, precipitable this class impurity of major part of removing.(3) salvianolic acid B is a slightly acidic class material, and it easily by macroporous resin adsorption, improves the separation and purification effect under acidic conditions.
Above water extraction and acidifying also can realize by one step of method with diluted acid aqueous solution extraction: the red sage root after salvia piece or the pulverizing is directly used diluted acid aqueous solution extraction, the pH value of diluted acid is 1～6, the optional organic acid of kind or the mineral acid of acid, method can be with pickling process or percolation process etc.
3. column chromatography separation, purifying salvianolic acid B
(1) adopts elite filler preparative chromatography post; (2) chromatographic column activation; (3) the water extract with the above-mentioned red sage root adds to chromatographic column, and water, diluted alcohol aqueous solution or water-acetone solvent wash-out is removed impurity; (4) with alcohol-water solution, water-acetone or the acetonitrile-aqueous solution wash-out of alcohols, acetonitrile or proper concn, obtain highly purified salvianolic acid B solution.
In above-mentioned steps (1), elite filler is meant that macroporous resin class, ion exchange resin, MCIGEL-CHP-20P, Sephadex LH-20 gel or C18, C8 bonding equate chromatographic column filler, and suggested design is for to do chromatographic column filler with the macroporous resin of nonpolar or low-pole.
In the above-mentioned steps (2), chromatographic column activatory method can be used the mixture of acetone, methyl alcohol, ethanol, acetonitrile organic solvent or itself and water, also available bases-aqueous solution, or alkali-alcoholic solution activation.
In the above-mentioned steps (3), can contain the acid or the inorganic salt of trace in the wash-out water.
In the above-mentioned steps (3), can singly wash with water and remove impurity, or single acetone-water solvent elution removal of impurity with diluted alcohol aqueous solution or lower concentration; Also can wash with water earlier and take off and then with the acetone-water solvent elution removal of impurity of diluted alcohol aqueous solution or lower concentration.
In the above-mentioned steps (3), the diluted alcohol aqueous solution equal solvent can be the aqueous solution of alcohol such as methyl alcohol, ethanol, propyl alcohol, butanols, also can adopt the aqueous solution of acetonitrile, or their mixture.
In the above-mentioned steps (3), the concentration of diluted alcohol aqueous solution equal solvent is generally below 50%, and commonly used is 10%-40%, the concentration of the most handy 20%-30%, the acetone-water solution of lower concentration acetone content commonly used is generally below 60%, and commonly used is 10%～50%, the most handy 20%～30% concentration.Elution process also can adopt the method for gradient, promptly earlier with the acetone-water eluant solution of lower concentration alcohol or lower concentration, and then with higher concentration alcohol or acetone soln equal solvent wash-out.
In the above-mentioned steps (4), in the acetone-water of proper concn, alcohol-water solution or the acetonitrile-aqueous solution, the organic phase proportion is generally greater than 10%, commonly usedly is 20%-90%, the concentration of the most handy 40%-70%.
4. dry
The drying of elutriant can adopt single stage method, also can adopt two-step approach.Two-step approach is under the condition of decompression or heating soup to be concentrated earlier, adopts spraying drying then, or vacuum-drying, method dryings such as thin film evaporation; Single stage method then is to adopt spraying drying, and methods such as thin film evaporation directly with above-mentioned steps 3 gained elutriant dryings, obtain the salvianolic acid B finished product.
The drying of elutriant also can adopt vacuum lyophilization according to the formulation needs in addition to the above methods; Or be sprayed directly on the solid, powdery pharmaceutical excipient, further dry again.
The preparation method of salvianolic acid B from salvia miltiorrhiza of the present invention owing to use water extraction, has avoided the appearance of water-insoluble compositions such as TANSHINONES; Adopt during extraction to be lower than 100 ℃ temperature, can avoid the destruction of salvianolic acid B; Be acidified with acid and the different salts of salvianolic acid B can be converted into single salvianolic acid B, can precipitate simultaneously and remove the impurity that extracts from red sage root crude drug, the column chromatography separating effect of salvianolic acid B is better under acidic conditions in addition; Owing in the process of wash-out decon, adopted water and lower concentration alcohol equal solvent, the impurity in the extracting solution further removed; In the elution process of effective ingredient salvianolic acid B,, make between other composition of the salvianolic acid B and the red sage root to have obtained separating preferably owing to adopted acetone-water, alcohol-water solution or the acetonitrile-aqueous solution of proper concn.Finally made the higher salvianolic acid B of purity, can make that the content of salvianolic acid B reaches more than 90% in the extract, and steady quality, technical maturity, can scale operation.Compare with other traditional preparation process method that contains red sage formulation, avoided the loss of main effective constituent salvianolic acid B in the red sage root,, make full use of tool such as Chinese material medicine resource and have very important significance improving red sage root curative effect.
Description of drawings
Fig. 1 is the sample chromatogram figure of the salvianolic acid B of embodiment one preparation;
Fig. 2 is salvianolic acid B from salvia miltiorrhiza standard substance color atlass.
Embodiment
Below in conjunction with specific embodiment, the present invention is described in further detail.
Embodiment one: the preparation method of salvianolic acid B, and its processing step is:
1. water extraction (pickling process): get salvia piece, weighing adds water by 10 times of amounts of its weight, soaking at room temperature 4 hours, 3 hours (but agitation as appropriate) of 60 ℃ of insulations then, separation and Extraction liquid; Residue is by 8 water extraordinarily of former salvia piece weight, 2 hours (but agitation as appropriate) of 60 ℃ of insulations, and separation and Extraction liquid merges extracted twice liquid, removes solid impurity in the extracting solution with filter method.
2. extracting solution acidifying: the hydrochloric acid that adds amount of filtrate 1～2% in filtrate is transferred pH, and the limit edged stirs, to pH value of filtrate be 1, left standstill then about two hours, make the abundant sedimentation of precipitate, centrifugal or suction filtration keeps supernatant liquor, discards precipitation.
3. column chromatography separation, purifying salvianolic acid B:
D101 type on the filtrate (production of Tianjin insecticide factory) macroporous resin column, upper prop sample (calculating with the crude drug dry weight) is 1: 4 (W: W) with the ratio of amount of resin, earlier with the water elution removal of impurity of about 30 times of column volumes, be that 30% ethanol aqueous wash removes impurity with the concentration of about 20 times of column volumes again.Be 50% aqueous ethanolic solution wash-out at last with concentration, with FeCl
3The content of salvianolic acid B in the point sample monitoring elutriant in conjunction with high performance liquid phase, elutes fully to salvianolic acid B, collects elutriant.
4. elutriant carries out vacuum concentration under the condition of 60 ℃ of temperature, vacuum tightness-0.1Mpa, reclaims ethanol content of dispersion about 5% to the concentrated solution, and concentrated solution is spray-dried again, makes salvianolic acid B from salvia miltiorrhiza.
Embodiment two: basic identical with embodiment one, different is that the water extraction process is a percolation process.Concrete grammar is as follows:
Get salvia piece, weighing is loaded in the diafiltration post or bucket that a synthetic glass makes, limit rim appropriate compacting, and about 1/5 volume is reserved in diafiltration post or bucket upper end.Add 40 ℃ of warm water to all medicinal material submergences, static immersion 4 hours.Open diafiltration post lower end valve, percolate is slowly flowed out, the amount that per hour flows out percolate is about a times of salvia piece dry weight, constantly injects about 40 ℃ of warm water simultaneously to diafiltration post upper end.With FeCl
3Point sample is observed the content of salvianolic acid B in the percolate, stops diafiltration when more weak to color reaction.
Embodiment three: basic identical with embodiment one, water extraction process that different is is with the 0.01mol/L dilute hydrochloric acid extraction, extracts and acidifying is once finished.
Embodiment four: basic identical with embodiment two, different is that the water extraction process is extracted with the 0.01mol/L dilute sulphuric acid, and extraction and acidifying are once finished.
Embodiment five: basic identical with embodiment one, different is that leaching process adopts ultrasonic extraction, and ultrasonic energy is 0.1 watt.
Embodiment six: basic identical with embodiment one, different is that leaching process adopts microwave extraction method, and microwave energy is 1 watt.
Embodiment seven: basic identical with embodiment one, and when different is the acidizing extracting liquid removal of impurity, be that to transfer pH value of filtrate with sulfuric acid be 1～4.
Embodiment eight: basic identical with embodiment one, and when different is the acidizing extracting liquid removal of impurity, be that to transfer pH value of filtrate with acetic acid be 1～4.
Embodiment nine: basic identical with embodiment one, and when different is the acidizing extracting liquid removal of impurity, be that to transfer pH value of filtrate with phosphoric acid be 1～4.
Embodiment ten: basic identical with embodiment one, and when different is the acidizing extracting liquid removal of impurity, be that to transfer pH value of filtrate with formic acid be 1～4.
Embodiment 11: basic identical with embodiment one, two, three, four, five or six, different is, separate at column chromatography, in the elution process of purifying salvianolic acid B, employing be methanol aqueous solution.
Embodiment 12: this is identical with the embodiment undecyl, and different is, separate at column chromatography, in the elution process of purifying salvianolic acid B, employing be aqueous propanol solution.
Embodiment 13: basic identical with embodiment one, different is, separate at column chromatography, in the elution process of purifying salvianolic acid B, employing be acetonitrile solution.
Embodiment 14: basic identical with embodiment one, different is, separate at column chromatography, in the elution process of purifying salvianolic acid B, employing be aqueous acetone solution.
Embodiment 15: basic identical with embodiment one, different is, separate at column chromatography, in the process of purifying salvianolic acid B, employing be that MCI-GEL CHP-20P makes the chromatogram column packing.
Embodiment 16: basic identical with embodiment one, different is, separate at column chromatography, in the process of purifying salvianolic acid B, employing be that the C18 bonding is made the chromatogram column packing mutually.
Embodiment 17: basic identical with embodiment one, different is, separate at column chromatography, in the process of purifying salvianolic acid B, employing be that ion exchange resin is made the chromatogram column packing.
Embodiment 18: basic identical with embodiment one, different is, separate at column chromatography, in the process of purifying salvianolic acid B, employing be that the C8 bonding is made the chromatogram column packing mutually.
Embodiment 19: basic identical with embodiment one, different is, separate at column chromatography, in the process of purifying salvianolic acid B, employing be that Sephadex LH-20 makes the chromatogram column packing.
The present invention's concrete technical scheme required for protection is not limited to the concrete combination of the expressed technical scheme of the foregoing description.
Claims (7)
1, a kind of preparation method of salvianolic acid B from salvia miltiorrhiza, its processing step is:
Step 1, water extraction
The water extraction process is with red sage root employing pickling process, percolation process, ultrasonic method or the microwave extraction method extraction of salvia piece or pulverizing, isolates the extracting solution that mainly contains red sage root water soluble ingredient; Employing filtration, natural sedimentation or centrifugal method are tentatively removed the solid impurity in the extracting solution;
Step 2, acidizing extracting liquid
Add mineral acid or organic acid accent pH value in extracting solution, making the steeping fluid pH value is 1～6, adopts filtration, natural sedimentation or centrifuging to remove the solid impurity that occurs after the acidifying;
Step 3, column chromatography separate, the purifying salvianolic acid B
A, employing filler preparative chromatography post, the filler that is adopted is macroporous resin class, ion exchange resin, MCIGEL-CHP-20P, SephadexLH-20 gel, C18 bonding phase or C8 bonded-phase chromatography column packing;
B, chromatographic column activation;
C, extracting solution is added to chromatographic column, water, diluted alcohol aqueous solution or water-acetone solvent wash-out is removed impurity;
D, usefulness alcohols, acetone, acetonitrile, alcohol solution, water-acetone soln or acetonitrile-aqueous solution wash-out obtain highly purified salvianolic acid B solution;
Step 4, drying.
2, the preparation method of the described salvianolic acid B from salvia miltiorrhiza of claim 1, it is characterized in that: water extraction and acidizing extracting liquid can be realized by one step of method with diluted acid aqueous solution extraction, be salvia piece or pulverize after the red sage root directly use diluted acid aqueous solution extraction, the pH value of diluted acid is 1～6, and the kind of acid is mineral acid or organic acid; The method of extracting can be pickling process, percolation process, ultrasonic method or microwave extraction method, isolates extracting solution, removes solid impurity in the extracting solution with filtration, natural sedimentation or centrifuging.
3, the preparation method of claim 1 or 2 described salvianolic acid B from salvia miltiorrhiza is characterized in that: step 3, column chromatography are separated, the step C of purifying salvianolic acid B is, and wash with water earlier and remove impurity, and then with diluted alcohol aqueous solution or acetone-water solvent elution, the removal of impurity.
4, the preparation method of claim 1 or 2 described salvianolic acid B from salvia miltiorrhiza, it is characterized in that: step 3, column chromatography separate, the step C of purifying salvianolic acid B is: wash with water earlier and remove impurity, use the acetone soln wash-out of lower concentration alcohol or lower concentration then, use the higher concentration alcohol or the removal of impurity of acetone soln wash-out again.
5, the preparation method of claim 1 or 2 described salvianolic acid B from salvia miltiorrhiza is characterized in that: step 4 adopts a step desiccating method or two step desiccating methods;
One step desiccating method is to adopt spraying drying, and the thin film evaporation method is directly with the elutriant drying of above-mentioned steps 3 gained;
Two-step approach is for evaporating under the condition of decompression or heating earlier, and soup concentrates, and adopts spraying drying then.
6, the preparation method of claim 1 or 2 described salvianolic acid B from salvia miltiorrhiza is characterized in that: step 4 adopts vacuum lyophilization.
7, the preparation method of claim 1 or 2 described salvianolic acid B from salvia miltiorrhiza is characterized in that: step 4 adopts and is sprayed directly on the solid, powdery pharmaceutical excipient, and is further dry again.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021607710A CN1164582C (en) | 2002-12-31 | 2002-12-31 | Process for preparing danshen salviandic acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021607710A CN1164582C (en) | 2002-12-31 | 2002-12-31 | Process for preparing danshen salviandic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1425659A true CN1425659A (en) | 2003-06-25 |
| CN1164582C CN1164582C (en) | 2004-09-01 |
Family
ID=4753472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021607710A Expired - Lifetime CN1164582C (en) | 2002-12-31 | 2002-12-31 | Process for preparing danshen salviandic acid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1164582C (en) |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305866C (en) * | 2003-08-19 | 2007-03-21 | 江苏扬子江药业集团有限公司 | Method of extracting phenolic components from chinese medicine red sage root and its freeze dried powder injection agent |
| CN100357306C (en) * | 2003-12-11 | 2007-12-26 | 中国医学科学院医药生物技术研究所 | Rosemary acid anhydride compound ,its preparation method and use for treatment and prevention of AIDS |
| CN100392400C (en) * | 2005-11-01 | 2008-06-04 | 上海中医药大学 | Method for pre processing sample in use for measuring concentration of salvianolic acid B, in biologic body fluid |
| CN100404040C (en) * | 2003-09-19 | 2008-07-23 | 天津天士力制药股份有限公司 | Medicinal composition for treating cardiopathy and its preparation method and use |
| CN100420682C (en) * | 2006-12-30 | 2008-09-24 | 山东省分析测试中心 | Separating preparation process of salvianolic acid B |
| WO2009076869A1 (en) * | 2007-12-07 | 2009-06-25 | Lichao Yuan | Salvianolic acid of high purity, preparation method and use thereof |
| CN1919253B (en) * | 2005-08-24 | 2010-12-01 | 天津天士力制药股份有限公司 | Cardiac and cerebral vascular disease treating medicinal composition |
| CN101168539B (en) * | 2007-12-04 | 2011-01-19 | 哈药集团中药二厂 | Method for extracting salvianolic acid B |
| CN101434590B (en) * | 2007-11-12 | 2011-03-23 | 北京科士蓝医药技术有限公司 | Preparation of salvianolic acid B pure product |
| CN101210002B (en) * | 2006-12-27 | 2011-04-20 | 中国科学院大连化学物理研究所 | Method for separating and preparing salvianolic acid B chemical reference substance |
| CN1981810B (en) * | 2005-12-14 | 2011-04-27 | 天津天士力制药股份有限公司 | Danshen component, preparation, making method and usage |
| CN1955171B (en) * | 2005-10-28 | 2011-04-27 | 山东绿叶天然药物研究开发有限公司 | Method for preparing red-rooted salvia phenolic acid B |
| CN102249920A (en) * | 2011-05-30 | 2011-11-23 | 上海朗萨医药科技有限公司 | Preparation method of high-purity salvianolic acid A |
| CN102304111A (en) * | 2011-07-12 | 2012-01-04 | 北京服装学院 | Method for extracting and purifying salvianolic acid B with ion exchange fiber |
| CN101759672B (en) * | 2008-11-28 | 2012-11-14 | 北京本草天源药物研究院 | Salvianolic acid B in radix salviae miltiorrhizae |
| CN103172601A (en) * | 2013-03-04 | 2013-06-26 | 西北大学 | Method for separating and extracting salvianolic acid B |
| CN103923043A (en) * | 2013-01-15 | 2014-07-16 | 天津天士力现代中药资源有限公司 | Method for effective preparation of salvianolic acid B extract |
| CN103923042A (en) * | 2013-01-15 | 2014-07-16 | 天津天士力现代中药资源有限公司 | Preparation method for salvianolic acid B extract |
| CN104910112A (en) * | 2015-04-28 | 2015-09-16 | 南京宸翔医药研究有限责任公司 | Preparation method, drug preparation and clinical application of high purity traditional Chinese medicine salvia miltiorrhiza active ingredient salvianolic acid B |
| CN105481809A (en) * | 2015-12-29 | 2016-04-13 | 山东大学 | Separation and purification method of salvianolic acid B and preparation method of salvianolic acid B magnesium salt |
| CN109988133A (en) * | 2018-01-03 | 2019-07-09 | 天津天士力之骄药业有限公司 | A kind of preparation method of danshinolic acid Y |
-
2002
- 2002-12-31 CN CNB021607710A patent/CN1164582C/en not_active Expired - Lifetime
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305866C (en) * | 2003-08-19 | 2007-03-21 | 江苏扬子江药业集团有限公司 | Method of extracting phenolic components from chinese medicine red sage root and its freeze dried powder injection agent |
| CN100404040C (en) * | 2003-09-19 | 2008-07-23 | 天津天士力制药股份有限公司 | Medicinal composition for treating cardiopathy and its preparation method and use |
| CN100357306C (en) * | 2003-12-11 | 2007-12-26 | 中国医学科学院医药生物技术研究所 | Rosemary acid anhydride compound ,its preparation method and use for treatment and prevention of AIDS |
| CN1919253B (en) * | 2005-08-24 | 2010-12-01 | 天津天士力制药股份有限公司 | Cardiac and cerebral vascular disease treating medicinal composition |
| CN1955171B (en) * | 2005-10-28 | 2011-04-27 | 山东绿叶天然药物研究开发有限公司 | Method for preparing red-rooted salvia phenolic acid B |
| CN100392400C (en) * | 2005-11-01 | 2008-06-04 | 上海中医药大学 | Method for pre processing sample in use for measuring concentration of salvianolic acid B, in biologic body fluid |
| CN1981810B (en) * | 2005-12-14 | 2011-04-27 | 天津天士力制药股份有限公司 | Danshen component, preparation, making method and usage |
| CN101210002B (en) * | 2006-12-27 | 2011-04-20 | 中国科学院大连化学物理研究所 | Method for separating and preparing salvianolic acid B chemical reference substance |
| CN100420682C (en) * | 2006-12-30 | 2008-09-24 | 山东省分析测试中心 | Separating preparation process of salvianolic acid B |
| CN101434590B (en) * | 2007-11-12 | 2011-03-23 | 北京科士蓝医药技术有限公司 | Preparation of salvianolic acid B pure product |
| CN101168539B (en) * | 2007-12-04 | 2011-01-19 | 哈药集团中药二厂 | Method for extracting salvianolic acid B |
| WO2009076869A1 (en) * | 2007-12-07 | 2009-06-25 | Lichao Yuan | Salvianolic acid of high purity, preparation method and use thereof |
| CN101759672B (en) * | 2008-11-28 | 2012-11-14 | 北京本草天源药物研究院 | Salvianolic acid B in radix salviae miltiorrhizae |
| CN102249920A (en) * | 2011-05-30 | 2011-11-23 | 上海朗萨医药科技有限公司 | Preparation method of high-purity salvianolic acid A |
| CN102249920B (en) * | 2011-05-30 | 2013-09-25 | 上海朗萨医药科技有限公司 | Preparation method of high-purity salvianolic acid A |
| CN102304111A (en) * | 2011-07-12 | 2012-01-04 | 北京服装学院 | Method for extracting and purifying salvianolic acid B with ion exchange fiber |
| CN103923043A (en) * | 2013-01-15 | 2014-07-16 | 天津天士力现代中药资源有限公司 | Method for effective preparation of salvianolic acid B extract |
| CN103923042A (en) * | 2013-01-15 | 2014-07-16 | 天津天士力现代中药资源有限公司 | Preparation method for salvianolic acid B extract |
| CN103172601A (en) * | 2013-03-04 | 2013-06-26 | 西北大学 | Method for separating and extracting salvianolic acid B |
| CN103172601B (en) * | 2013-03-04 | 2014-10-22 | 西北大学 | Method for separating and extracting salvianolic acid B |
| CN104910112A (en) * | 2015-04-28 | 2015-09-16 | 南京宸翔医药研究有限责任公司 | Preparation method, drug preparation and clinical application of high purity traditional Chinese medicine salvia miltiorrhiza active ingredient salvianolic acid B |
| CN105481809A (en) * | 2015-12-29 | 2016-04-13 | 山东大学 | Separation and purification method of salvianolic acid B and preparation method of salvianolic acid B magnesium salt |
| CN109988133A (en) * | 2018-01-03 | 2019-07-09 | 天津天士力之骄药业有限公司 | A kind of preparation method of danshinolic acid Y |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1164582C (en) | 2004-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1164582C (en) | Process for preparing danshen salviandic acid | |
| CN1830947A (en) | Method for extracting 'Danfen' phenolic acid-A | |
| CN101585885A (en) | Method for preparing polygonatum odoratum polysaccharide | |
| CN101049331A (en) | Preparation method for extracting purified general saponin from notoginseng of Chinese traditional medicine | |
| CN100439319C (en) | Method for preparing salviol acid A | |
| CN101348474A (en) | Method for preparing salvianolic acid B and tanshinol from Salvia miltiorrhiza stem | |
| CN1887849A (en) | Salvianolic acid A preparing process | |
| CN103180334B (en) | Prepare the method for lactone glucoside of Radix Paeoniae and peoniflorin | |
| CN1436553A (en) | Method of extracting effective component in red sage | |
| CN101041620A (en) | Preparation method of salvia miltiorrhiza tanshinoate A | |
| CN101401843B (en) | Extracting method for active principle of traditional Chinese medicine red sage root | |
| CN107629140A (en) | A kind of method of ionic liquid double-aqueous phase system extraction Goods-Flow Plan | |
| CN110066305B (en) | Mechanochemical extraction method for preparing crude naphthopyrone extract from berchemilla lineate | |
| CN1189176C (en) | Astragalus root methyl-glycoside composition and preparation method | |
| CN1515582A (en) | Preparation method of low-acid ginkgo leaf extract | |
| CN1939458A (en) | Preparation of gardenia jasminoides by macroporous adsorbing resin | |
| CN1989984A (en) | Chuanxiong rhizome effective ingredient, preparing method, preparation and use thereof | |
| CN100344300C (en) | Cyclodextrin super molecular composition of Chinese medicine giant knutweed rhizome and its preparing method | |
| CN1911272A (en) | Powder injection contg. high content tanshin polyphenolic acid salts, and its prepn. method | |
| CN101647858B (en) | Preparation method of water-soluble extract of red sage root | |
| CN1817351A (en) | Production of variolaria amra medicinal extract and its medicinal preparation | |
| CN102675408B (en) | A kind of preparation method of Tanshinone II A | |
| CN102675407B (en) | A kind of preparation method of Cryptotanshinone | |
| CN1682825A (en) | Method for preparing compound red sage roo drip liquid | |
| CN1583131A (en) | Frozen dry powder injection of composite salvia miltiorrhiza and its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: NANJING XIANANHUI MEDICINE ENGINEERING INSTITUTE Free format text: FORMER OWNER: HONGQIAO MEDICINE TECHNOLOGY INST., NANJING Effective date: 20081031 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20081031 Address after: Room 3, building 10, Taiping Gate Street, Xuanwu District, Nanjing, Jiangsu, China 704 Patentee after: Nanjing first Hui Medical Engineering Research Institute Co.,Ltd. Address before: 2 floor, 75 Gulou Street, Gulou District, Jiangsu, Nanjing Patentee before: Nanjing Hongqiao Medical Technology Research Institute |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhu Zhibin Document name: Notification to Pay the Fees |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhu Zhibin Document name: Notification of Termination of Patent Right |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhu Zhibin Document name: Resume right request approval decision |
|
| ASS | Succession or assignment of patent right |
Owner name: HONGQIAO MEDICINE TECHNOLOGY INST., NANJING Free format text: FORMER OWNER: NANJING XIANHUI MEDICAL ENGINEERING INSTITUTE CO., LTD. Effective date: 20150609 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210016 NANJING, JIANGSU PROVINCE TO: 210029 NANJING, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150609 Address after: 210029 room 5, building 282, 302 Hanzhoung Road, Gulou District, Jiangsu, Nanjing Patentee after: Nanjing Hongqiao Medical Technology Research Institute Address before: 704 room 3, building 10, 210016 Taiping Street, Xuanwu District, Jiangsu, Nanjing Patentee before: Nanjing first Hui Medical Engineering Research Institute Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180927 Address after: 225316 Jiangsu City, Taizhou, Hailing District, drug City Road No. 1 new drug innovation base two phase D building 7807 room Patentee after: Jiangsu new Materia Medica Research Institute Co.,Ltd. Address before: 210029 302, room 5, 282 Hanzhoung Road, Gulou District, Nanjing, Jiangsu. Patentee before: Nanjing Hongqiao Medical Technology Research Institute |
|
| CX01 | Expiry of patent term |
Granted publication date: 20040901 |
|
| CX01 | Expiry of patent term |